Altimmune to present new data on the lipidomic profile in subjects treated with pemvidutide at the liver meeting® 2024

Gaithersburg, md., oct. 15, 2024 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that new data showing reductions of multiple classes of atherogenic and cardio-inflammatory lipids in subjects treated with pemvidutide will be presented in a poster session at the liver meeting® 2024 of the american association for the study of liver diseases (aasld) in san diego, ca taking place november 15-19, 2024. the data were derived from altimmune's 12-week phase 1b randomized, placebo-controlled study in subjects with metabolic dysfunction-associated steatotic liver disease (masld), a precursor to the more serious metabolic dysfunction-associated steatohepatitis (mash). the company has completed enrollment in a phase 2b efficacy trial of pemvidutide in patients with biopsy-confirmed f2/f3 mash, with topline data expected in the second quarter of 2025.
ALT Ratings Summary
ALT Quant Ranking